Neurology® Podcast

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

1) Fingolimod after natalizumab and the risk of short-term relapse and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Vilija Jokubaitis about her paper on fingolimod after natalizumab and the risk of short-term relapse. Dr. Adam Numis is reading our e-Pearl of the week about cardiac cephalgia. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Madeline Fields about epilepsy therapeutics: Clobazam. The participants had nothing to disclose except Drs. Keegan, Jokubaitis and Numis.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Jokubaitis received funding for travel to speak at a conference from Novartis, receives research support from MSBase Foundation and National Health and Medical Research Council.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

Interviews from the 2013 AAN Annual Meeting

1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French.Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.

1) Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. William Powers about his paper on lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Dr. Roy Strowd is reading our e-Pearl of the week about Déjà vu. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Doug Turnbull about the management of mitochondrial disorders. The participants had nothing to disclose except Drs. Southerland, Powers and Strowd.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Powers serves as an editorial board member of Stroke and Journal of Cerebral Blood Flow and Metabolism; serves on the scientific advisory board for Ontario Brain Institute Morehouse School of Medicine; receives research support from the NIH and UNC.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Benjamin Friedman about his paper on intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine. Dr. Roy Strowd is reading our e-Pearl of the week about evaluating the exome. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Robert Taylor about the investigations for mitochondrial disorders. The participants had nothing to disclose except Drs. Friedman and Strowd.Dr. Friedman serves on the scientific advisory board for MAP Pharmaceuticals.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Submandibular gland needle biopsy for diagnosis of Parkinson disease and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Brown interviews Dr. Charles Adler about his paper on submandibular gland needle biopsy for diagnosis of Parkinson disease. Dr. Roy Strowd is reading our e-Pearl of the week about nodes needing neurofascin. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Andrew Schaefer about syndromes of mitochondrial disorders. The participants had nothing to disclose except Drs. Adler and Strowd.Dr. Adler serves on the scientific advisory board of Bachmann Strauss Dystonia and Parkinson Foundation; is a consultant for Allergan, Inc., Novartis, Merz Pharmaceuticals, LLC, XenoPort, Inc.; receives royalties from the publication of the book Parkinson's Disease and Movement Disorders; receives research support from Avid Radiopharmaceuticals, Department of Defense, Michael J. Fox Foundation for Parkinson's Disease Research, National Parkinson's Foundation and NIH.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Clinical characteristics and outcome of brain abscess and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Cupka interviews Dr. Matthijs Brouwer about his paper on clinical characteristics and outcome of brain abscess. Dr. Roy Strowd is reading our e-Pearl of the week about angioedema after tPA. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Grainne Gorman about the fundamental principles of mitochondrial disorders. The participants had nothing to disclose except Drs. Brouwer, Strowd and Gorman.Dr. Brouwer receives research support from the Dutch Scientific Organization; received research support from the European Federation of Neurological Sciences and European Society of Clinical Microbiology and Infectious Diseases.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gorman receives research support from the UK NIHR Biomedical Research Centre for Aging and Age-related disease, Research Fellow, awarded to the Newcastle upon Tyne Trust Foundation Hospitals NHS Trust.

Interviews from the 2013 AAN Annual Meeting

1) Guideline on prevention of stroke in nonvalvular atrial fibrillation. and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Gary Gronseth about AAN paper on prevention of stroke in nonvalvular atrial fibrillation. Dr. James Addington is reading our e-Pearl of the week about superficial siderosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about Edoxaban, non-pharmaceutical options for stroke prevention in afib: ablation, atrial appendage occluder devices and any other options. The participants had nothing to disclose except Drs. Kissela, Gronseth, Addington, Southerland and Chaturvedi.Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring and provides medico-legal reviews.Dr. Gronseth serves as Associate Editor for for Neurology®; serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.